Targeted 1,3-dipolar cycloaddition with acrolein for cancer prodrug activation†

Cytotoxic anticancer drugs used in chemotherapy are often antiproliferative agents that preferentially kill rapidly growing cancer cells. Their mechanism relies mainly on the enhanced proliferation rate of cancer cells and is not genuinely selective for cancer cells. Therefore, these drugs can also significantly affect healthy cells. Prodrug therapy provides an alternative approach using a less cytotoxic form of anticancer drug. It involves the synthesis of inactive drug derivatives which are converted to an active form inside the body and, preferably, only at the site of cancerous tissues, thereby reducing adverse drug reaction (ADR) events. Herein, we demonstrate a prodrug activation strategy by utilizing the reaction between aryl azide and endogenous acrolein. Since acrolein is generally overproduced by most cancer cells, we anticipate our strategy as a starting point for further applications in mouse models with various cancers. Furthermore, cancer drugs that have had therapeutic index challenges might be reconsidered for application by utilizing our strategy.

Automated summary

Cytotoxic anticancer drugs target rapidly growing cancer cells but can also affect healthy cells. Prodrug therapy offers a less toxic alternative by converting inactive drug derivatives inside the body, potentially reducing adverse reactions. Utilizing a prodrug activation strategy involving aryl azide and endogenous acrolein may have applications in mouse models with different cancers and could help with drugs facing therapeutic index challenges.